Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Figure: Results by market cap

    Grow early, grow often Results by market cap The top market cap tier — companies valued above $5 billion — outperformed all other market cap segments in 2014, gaining 32% on the year. Of the 31 companies in the …

    Published on 1/5/2015
  • Table: 4Q approvals and setbacks

    Grow early, grow often 4Q approvals Selected fourth quarter approvals. (A) Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is being acquired by Merck & Co. Inc. (NYSE:MRK) Company Approval AbbVie Inc. (NYSE:ABBV)/…

    Published on 1/5/2015
  • Table: Index performance

    Grow early, grow often Index performance The BioCentury 100, NYSE Arca Biotechnology (BTK) and NASDAQ Biotechnology (NBI) indices all ended the year well ahead of the general market benchmarks. The BC100 lagged …

    Published on 1/5/2015
  • Table: Restructuring watch

    Grow early, grow often Restructuring watch At least two companies reported workforce reductions in the fourth quarter compared to at least 13 in the same period last year. Tied with 1Q14, this is the smallest …

    Published on 1/5/2015
  • 2015 Financial Markets Preview: Show me in 2015

    How buysiders expect maturing sector to deliver growth in 2015

    Buysiders expect 2015 to be driven by mature large caps while follow-ons will be open for small caps that deliver on expectations.

    Published on 1/5/2015
  • Figure: Healthcare/biotech fund flows

    Show me in 2015 Healthcare/biotech fund flows More than $6 billion flowed into healthcare/biotech funds last quarter, bringing net fund flows to $18 billion for the year. The S&P 500 Health Care Index gained 7% …

    Published on 1/5/2015
  • Figure: M&A activity

    Show me in 2015 M&A activity The aggregate transaction value for M&A deals completed in 2014 reached a record $86 billion, beating the previous high of $80 billion in deals in 2011 and more than 2.6x the $32.5 …

    Published on 1/5/2015
  • Figure: Price-to-earnings: BT vs RX

    Grow early, grow often Price-to-earnings: BT vs RX The average biotech P/E ended the year at 22.4, about 1.3x the 17.7 average for big pharma. A year ago, biotech's P/E was 1.6x big pharma's multiple. The 13% …

    Published on 1/5/2015
  • Figure: Raised by market cap

    Show me in 2015 Raised by market cap In 2014, 467 public companies raised $45.5 billion vs. 401 companies that raised $31.2 billion in 2013. The increase was bolstered by large debt financings from a handful of …

    Published on 1/5/2015
  • Table: Follow-on performance

    Show me in 2015 Follow-on performance In 2014, $11 billion was raised via 150 follow-on offerings, above the $10 billion raised from 139 deals in 2013. The 2014 class is up a median of 14% from their postmoney …

    Published on 1/5/2015
  • Table: IPO performance

    Show me in 2015 IPO performance Twenty-three companies raised $2.1 billion in IPOs in 4Q14, bringing the total for 2014 to 112 companies that raised $9 billion. In 2013, 60 IPOs raised $3.9 billion. The median …

    Published on 1/5/2015
  • Table: IPO queue

    Show me in 2015 IPO queue Fourteen companies have announced plans to go public since the start of 4Q14, bringing the IPO queue to at least 31. Unless noted, companies are seeking to list on NASDAQ. (A) If proposed…

    Published on 1/5/2015
  • Back for more

    Tallying Vivo's recent exits as VC raises $428M for eighth fund

    Finance Back for more About three years after closing its last fund, Vivo Capital (formerly Vivo Ventures) has come back for more. The firm raised $428 million for an eighth fund, according to a December SEC filing…

    Published on 1/5/2015
  • Venture harvest

    Totting up the banner year for life science VCs, private biotechs

    Finance Ebb & Flow Venture harvest Figure: Money Raised in 2014 Private biotechs and the venture and private equity funds they rely on are continuing to reap the benefits of the public biotech bull market and …

    Published on 1/5/2015
  • Figure: Money Raised in 2014

    Venture harvest Money Raised in 2014 In the last two weeks, the biotech industry raised $344 million, bringing to $54.5 billion the total raised year-to-date. In 2014, a total of $54.5 billion was raised, …

    Published on 1/5/2015
  • 4Q14 Stock Wrap-up: Grow early, grow often

    Winners, losers in biotech stock tiers in 4Q14

    Biotech stocks rose in all but the microcap tier in 4Q14, with strong showings by recent IPO companies.

    Published on 1/5/2015
  • Flexible funding for CRT

    CRT Pioneer Fund's plans for its latest cash influx

    Finance Flexible funding for CRT CRT Pioneer Fund's latest close triples the number of cancer programs the fund can move through development compared with its expectations when it launched two years ago. Last week…

    Published on 12/22/2014
  • Falling for HER

    Immunogen sinks on prospects for Kadcyla in first-line breast cancer.

    Finance Falling for HER Judging by the $407 million haircut ImmunoGen Inc. (NASDAQ:IMGN) took on Friday, investors have lost almost all confidence in Kadcyla ado-trastuzumab emtansine being used as a first-line …

    Published on 12/22/2014
  • Out with a bang

    Juno closes 2014 with biggest IPO for a clinical-stage, U.S.-listed biotech

    Finance Ebb & Flow Out with a bang Figure: Money Raised in 2014 Juno Therapeutics Inc. (NASDAQ:JUNO) last week completed the largest IPO with the largest post-money valuation for a clinical-stage biotech on a U…

    Published on 12/22/2014
  • Figure: Money Raised in 2014

    Out with a bang Money Raised in 2014 Last week, the biotech industry raised $1,040 million, bringing to $54 billion the total raised year-to-date. In 2013, a total of $37.1 billion was raised, including $14.4 …

    Published on 12/22/2014
  • Unlocking autoimmune diseases

    What autoimmune play Padlock plans to do with $23M A round

    Finance Unlocking autoimmune diseases Padlock Therapeutics Inc. plans to use last week's $23 million series A round to develop a pipeline of small molecule PAD inhibitors for autoimmune diseases, with the near-term…

    Published on 12/22/2014
  • Annexon connections

    Why Novartis Venture backed neurodegeneration play Annexon's $34M A-1 round

    Finance Annexon connections Novartis Venture Fund recruited a syndicate to back Annexon Bioscience's complement modulating approach to target a key step in neurodegeneration arising from different causes. Those …

    Published on 12/22/2014
  • Avanir Chronicles

    Charting Avanir's course from Lidak Pharmaceuticals to Otsuka takeout target

    Avanir chronicles The $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal …

    Published on 12/15/2014
  • Uphill road for Cubist CVRs

    Merck taking over Trius, Optimer CVRs, but neither looks likely to pay out

    Ebb & Flow Uphill road for Cubist CVRs Figure: Money Raised in 2014 When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the …

    Published on 12/15/2014
  • Pollen for Anergis

    Series B to move Anergis to Phase III with rapid vaccine for birch pollen allergy

    Ebb & Flow Pollen for Anergis By topping off its series B financing, Anergis S.A. hopes to make its short-term birch pollen allergy vaccine into a long-term winner. The additional CHF14.5 million ($15 million) in …

    Published on 12/15/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993